GSK (GSK) in Talks to Acquire Nuvalent for Over $9 Billion

AI Summary

GSK (GSK) is in discussions to acquire cancer biotech firm Nuvalent for more than $9 billion. This potential deal would be among GSK's largest acquisitions to date and comes amid a rise in M&A activity within the biotech sector this year. Such a transaction would enhance GSK's portfolio in cancer treatment and reflect a strategic shift in their business operations. The increase in M&A in the biotech industry signals potential growth opportunities for companies like GSK.